Iniciar sesión Regístrese gratis

Starpharma Ingresos Y/Y

¿Qué es el Ingresos Y/Y de Starpharma?

El Ingresos Y/Y de Starpharma Holdings Limited es 131.75%

¿Cuál es la definición de Ingresos Y/Y?

El crecimiento anual de los ingresos de los últimos 3 años es el crecimiento de los ingresos de un año a otro promediado en los últimos 3 años.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Ingresos Y/Y de compañías en Sector Health Care en ASX en comparadas con Starpharma

¿Qué hace Starpharma?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Empresas con ingresos y/y similar a Starpharma